 | This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
Alexey Karpenko (also Oleksiy Viktorovych Karpenko, born 1949 in Ukraine) is a Ukrainian psychophysiologist and cell transplantologist.
The daughter of Alexey Karpenko is a Ukrainian singer, composer and poet Olena Karpenko (stage-name Solomia, born 1981).
Graduated from high school in Donetsk, Ukraine (1966) and from Kyiv Medical University, Ukraine (1972) as a medical doctor, PhD (1977), Doctor of Sciences (1989). [1]
Worked at the Institute for Occupational Health of Ukrainian Academy of Medical Science (1972-1995) in scientific field of psychophysiology of mental labor. He created original methods, designed and implemented self-educating adaptive computer-based systems for individual psychophysiological monitoring and optimization of current professional reliability and mental capacity of operators at nuclear and heat power plants, major electric grids and cosmonautics. [2] [3]
In 1989-1995 he headed the scientific program for psychophysiological grounds of the professional reliability in operative personnel of the Ministry of Energetics of Ukraine. [4] In 2002-2010 he participated in creation of branch legislation for implementation of psychophysiological systems which support professional reliability and high efficiency of operative personnel. [5]
Together with Dr. Alexander Smikodub Dr. Alexey Karpenko founded the Embryonic Tissue Center “EmCell” (1994) and was General Director (CEO) of “EmCell” during 1994-2001. In 1994, “EmCell” jointly with National Medical University and Administration of the city of Kyiv founded the world's first clinic totally dedicated to clinical application of fetal stem cell transplantations (Cell Therapy Clinic “EmCell”).
When Dr. Alexey Karpenko was CEO “EmCell” was granted letters of patent for new methods of treatment with the use of Fetal Stem Cell Transplantations by Ukraine, the US, Netherlands, Greece and Russia [6] [7] [8] and took part in dozens of international congresses and conferences with contributions regarding clinical use of Fetal Stem Cell Transplantations. [9]
Media paid attention to the pioneering work of "Emcell" with wide range of appreciation and critic. [10] [11]
At this time, Center "EmCell" in cooperation with six leading research institutes and universities of Ukraine developed legal grounds for practical clinical use of Fetal Stem Cell Transplantation, which were duly approved by Ministry of Health and by Academy of Medical Sciences of Ukraine (1999-2001).
In 2001, Alexey Karpenko left “EmCell” to create and to lead the Department for Fetal Stem Cell Transplantation at the Coordinating Center for Transplantation of Organs, Tissues and Cells of the Ministry of Health of Ukraine (2001-2003). [12] [13]
Starting from 2010, Dr. Alexey Karpenko is the Honorary Scientific Director of the Center “EmCell”.
| External videos | |
|---|---|
 The EmCell Experience - The God Cells: A Fetal Stem Cell Journey on YouTube |
Dr. Alexey Karpenko was featured in the American documentary “The God Cells: A Fetal Stem Cells Journey” (2017) [14]
In multicellular organisms, stem cells are undifferentiated or partially differentiated cells that can differentiate into various types of cells and proliferate indefinitely to produce more of the same stem cell. They are the earliest type of cell in a cell lineage. They are found in both embryonic and adult organisms, but they have slightly different properties in each. They are usually distinguished from progenitor cells, which cannot divide indefinitely, and precursor or blast cells, which are usually committed to differentiating into one cell type.
The amniotic fluid is the protective liquid contained by the amniotic sac of a gravid amniote. This fluid serves as a cushion for the growing fetus, but also serves to facilitate the exchange of nutrients, water, and biochemical products between mother and fetus.
Cell therapy is a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, for example, by transplanting T-cells capable of fighting cancer cells via cell-mediated immunity in the course of immunotherapy, or grafting stem cells to regenerate diseased tissues.
Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. As of 2016, the only established therapy using stem cells is hematopoietic stem cell transplantation. This usually takes the form of a bone-marrow transplantation, but the cells can also be derived from umbilical cord blood. Research is underway to develop various sources for stem cells as well as to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes and heart disease.
Anthony Atala is an American bioengineer, urologist, and pediatric surgeon. He is the W.H. Boyce professor of urology, the founding director of the Wake Forest Institute for Regenerative Medicine, and the chair of the Department of Urology at Wake Forest School of Medicine in North Carolina. His work focuses on the science of regenerative medicine: "a practice that aims to refurbish diseased or damaged tissue using the body's own healthy cells".
A biological pacemaker is one or more types of cellular components that, when "implanted or injected into certain regions of the heart," produce specific electrical stimuli that mimic that of the body's natural pacemaker cells. Biological pacemakers are indicated for issues such as heart block, slow heart rate, and asynchronous heart ventricle contractions.
William C. Rader is an American psychiatrist. After an early career treating eating disorders, he founded several offshore clinics administering injections of human fetal stem cells claiming clinically-unproven therapeutic benefits for a variety of illnesses. Rader's assertions about the effectiveness of his injections, coupled with high-pressure sales tactics, aroused intense criticism. Complaints by patients led to the revocation of his medical license in California.
Sally Temple is an American developmental neuroscientist in Albany, New York. She is a co-founder and scientific director for The Neural Stem Cell Institute and is a professor of Neuroscience and Neuropharmacology at Albany Medical College Temple is also the principal investigator in her laboratory that focuses on neural stem cells and therapies for neurological-related disorders
ISMETT, in Italian, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione translated as the Mediterranean Institute for Transplantation and Advanced Specialized Therapies, is a center for organ transplantation located in Palermo, Italy. ISMETT was founded in 1997 as a partnership between the Region of Sicily, the Civico and Cervello hospitals in Palermo, and the University of Pittsburgh Medical Center (UPMC).
Arthur L. Jenkins III is an American fellowship-trained neurosurgeon, co-director of the Neurosurgical Spine Program, and Director of Spinal Oncology and Minimally Invasive Spinal Surgery (MIS) Program at the Mount Sinai Hospital, New York. Additionally, he is an associate professor of Neurosurgery and of Orthopedic Surgery at the Mount Sinai School of Medicine. Dr. Jenkins has multiple patents and patent applications for spine-related implants and support systems, and is developing new minimally invasive treatments for patients with cancer that has spread to the spine. He is an innovator in the treatment of acute spinal cord injury as well as degenerative and congenital anomalies of the spine, taking a minimally invasive or minimal-impact approach where possible. He is board certified in Neurological Surgery and is licensed in New York and Connecticut.
Stamina therapy was a controversial and unproven treatment marketed in Italy by convicted quack Davide Vannoni during 2007–2014. Mainly aimed at neurodegenerative diseases, the method relied on the conversion of mesenchymal stem cells into neurons. Its details were kept secret by its promoters and Vannoni has never published any details in a scientific journal. In the absence of scientific validation, claims of its therapeutic effectiveness are unproven.
Diana W. Bianchi is the director of the U.S. National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development, a post often called “the nation’s pediatrician.” She is a medical geneticist and neonatologist noted for her research on fetal cell microchimerism and prenatal testing. Bianchi had previously been the Natalie V. Zucker Professor of Pediatrics, Obstetrics, and Gynecology at Tufts University School of Medicine and founder and executive director of the Mother Infant Research Institute at Tufts Medical Center. She also has served as Vice Chair for Research in the Department of Pediatrics at the Floating Hospital for Children at Tufts Medical Center.
Jane Visvader is a scientist specialising in breast cancer research who works for the Walter and Eliza Hall Institute in Melbourne, Australia. She is the joint head of the Breast Cancer Laboratory with Geoff Lindeman.
Karin J. Blakemore is a leading medical geneticist and works in gynecology and obstetrics, human genetics, and maternal and fetal medicine. Dr. Blakemore's major contribution to medicine stems from her research as a member of a team that aimed to fight genetic disorders through the in utero transplantation of donor cells using a mouse as an animal model. Through this initial research in regards to first trimester prenatal diagnosis, Blakemore initiated the beginning of research on in utero bone marrow transplantation for genetic disorders of the fetus.
Dr Hargovind Laxmishanker "H. L." Trivedi was an Indian nephrologist, immunologist, transplant surgeon and stem cell researcher.
Lorenz Studer is a Swiss biologist. He is the founder and director of the Center for Stem Cell Biology at Memorial-Sloan Kettering Cancer Center in New York City. He is a developmental biologist and neuroscientist who is pioneering the generation of midbrain dopamine neurons for transplantation and clinical applications. His expertise in cell engineering spans a wide range of cells/tissues within the nervous system geared toward disease modeling and exploring cell replacement therapy. Currently, he is a member of the Developmental Biology Program and Department of Neurosurgery at Memorial Sloan-Kettering Cancer Center and a Professor of Neuroscience at Weill Cornell Medical College in New York City, NY.
Andrew Louis Pecora is an American hematologist and oncologist involved in research on the use of stem cells and oncolytic viruses to treat diseases, including cancer. He is the CEO of Outcomes Matter Innovations. As of 2020, he is on the Board of Directors Celularity, Inc. (since 2017) and founder and Executive Chairman, COTA, Inc.. Previously, he was chief innovations officer, professor and vice president of cancer services at the John Theurer Cancer Center, part of the Hackensack University Medical Center. He is a professor of medicine and oncology at Georgetown University.
Geeta Kashyap Vemuganti is an Indian ocular pathologist and the head of the department at the Ophthalmic Pathology Service and Stem Cell Laboratory of the L. V. Prasad Eye Institute (LVPEI). She is also a dean and professor at the school of medical sciences of the University of Hyderabad.
Stem cell therapy for macular degeneration is the use of stem cells to heal, replace dead or damaged cells of the macula in the retina. Stem cell based therapies using bone marrow stem cells as well as retinal pigment epithelial transplantation are being studied. A number of trials have occurred in humans with encouraging results.
Foetal brain cell graft is a surgical procedure that can be used as a regenerative treatment for various neurological conditions, but was mainly explored and used specifically for treating Parkinson's disease (PD). A standardised procedure is followed: the cells are usually obtained from a 7–8 weeks old foetus and the collected cells undergo testing to examine whether they are free from infectious agents and safe for transplantation. It is found that this procedure results in an overall improvement in motor functions and a reduction in reliance on medication for PD patients.
